Recro Enters Into Master Commercial Supply And Services Agreement With Otsuka

• Agreement Establishes Recro as Commercial Supplier for Otsuka
• Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier

Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the signing of a master supply and services agreement with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”). Under terms of the agreement, Recro will serve as a commercial manufacturing and supplier for Otsuka.

“The opportunity to support Otsuka’s supply chain risk management efforts while serving as their U.S.-based supply source represents a key milestone for Recro and underscores the continued momentum our company is generating in growing our CDMO business and diversifying our client base. This is a significant win for Recro and is a testimony to the hard work our tech transfer and production teams have put in over the past several quarters to get us to this point,” said David Enloe, chief executive officer of Recro. “We look forward to a long and productive collaboration with the Otsuka team as we support them in achieving commercial success across their product portfolio. Beyond our work with Otsuka, we believe this agreement highlights Recro’s ability to serve as a trusted U.S. supply source for other developers of small molecule therapeutics, thus helping to mitigate the growing global supply chain risk facing the biopharmaceutical industry.”

About Recro
Recro is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

For more information, visit recrocdmo.com.